Which therapy is used for Irvine-Gass Syndrome?

Which therapy is used for Irvine-Gass Syndrome?

• A. Ketorolac 0.5% QID and Prednisolone acetate 1% QID with slow taper
• B. Anti-VEGF
• C. Acetazolamide
• D. Vitamin A

Answer: (A)

Irvine-Gass syndrome is postoperative cystoid macular edema after cataract surgery, caused by inflammation that makes the blood-retinal barrier leak fluid into the macula. The goal of treatment is to quell inflammation and reduce prostaglandin-driven vascular permeability to restore macular integrity. Using a combination of a topical NSAID (such as ketorolac) and a topical corticosteroid (such as prednisolone acetate) with a slow taper directly addresses these goals. The NSAID blocks prostaglandin synthesis, which helps decrease the leakage that produces CME, while the steroid suppresses the broader inflammatory response and supports recovery of the blood-retinal barrier. This dual approach has proven effective in resolving postoperative CME and preserving vision. Other options are less fitting as initial therapy for this condition. Anti-VEGF treatments are geared more toward edema from other diseases like diabetic macular edema or vein occlusions. Acetazolamide can be used in some CME scenarios but is not the standard frontline treatment for Irvine-Gass syndrome. Vitamin A has no role in managing this condition.

Irvine-Gass syndrome is postoperative cystoid macular edema after cataract surgery, caused by inflammation that makes the blood-retinal barrier leak fluid into the macula. The goal of treatment is to quell inflammation and reduce prostaglandin-driven vascular permeability to restore macular integrity.

Using a combination of a topical NSAID (such as ketorolac) and a topical corticosteroid (such as prednisolone acetate) with a slow taper directly addresses these goals. The NSAID blocks prostaglandin synthesis, which helps decrease the leakage that produces CME, while the steroid suppresses the broader inflammatory response and supports recovery of the blood-retinal barrier. This dual approach has proven effective in resolving postoperative CME and preserving vision.

Other options are less fitting as initial therapy for this condition. Anti-VEGF treatments are geared more toward edema from other diseases like diabetic macular edema or vein occlusions. Acetazolamide can be used in some CME scenarios but is not the standard frontline treatment for Irvine-Gass syndrome. Vitamin A has no role in managing this condition.